Life Clips Inc (fka LCLP)

[2dollarbill]

LCLP merger DD: LifeClips CEO

Ms. Victoria D. Rudman serves as the Company's Interim Chief Executive Officer, and Chief Financial Officer, Director.

THERAKINE CFO
She also serves as the Chief Financial Officer of TheraKine Ltd., a private company involved in drug delivery technologies.

KALYTERA CFO
She also serves as Chief Financial Officer, Treasurer,and Secretary of Kalytera Theraputics, a company involved in Cannabinoid theraputics.

https://www.cmocro.com/company/TheraKine%2C+Inc./index.html

TheraKline is developing an injectable, sustained-release technology that will allow any biological drug to be formulated for months of stable, controlled release. It's a platform that could soon make local delivery of biologic agents and small molecules safer, more better-than-expected results in its preliminary testing of the duration of a matrix release of the drug Naltrexone, an opioid receptor antagonist used primarily in the management of alcohol and opioid dependence. If further testing of the sustained-release system goes as well, TheraKine could soon supply the only inter-muscular' programmable release of Neltraxone available anywhere. It is believed by some experts that the worldwide market for the 10 most popular drug delivery technologies alone could grow to $81.5 billion in just two years. TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity. The potential is limitless.

https://kalytera.co/about/

Kalytera Therapeutics, Inc. is pioneering the development of CBD therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on GVHD and treatment of acute and chronic pain. Kalytera’s Exclusive Option to License Proprietary Medical Cannabis Formulation for the Treatment of Psoriasis. The global psoriasis drug market is expected to be valued at US$21.4 billion by 2022, according to a new market research report by Grand View Research, Inc., and the rising prevalence and incidence of psoriasis is anticipated to fuel the market’s growth. Severe psoriasis is currently treated with monoclonal antibody therapeutics costing more than US$25,000 per year, and Kalytera will seek to bring to market a potentially safer, more effective, and less expensive medical cannabis extract for the treatment of severe psoriasis.